Rite Aid realizes 0.4% March gain with sales of $1.9 billion
CAMP HILL, Pa. — Rite Aid on Thursday posted $1.9 billion in sales for the four weeks ended March 29, up 0.4%.
Same-store sales increased 0.7% over the prior-year period. March front-end same store sales decreased 5%, with 4.1% of the decrease attributable to a shift in the timing of Easter, which falls on April 20 this year compared to March 31 last year.
Pharmacy same-store sales, which included an approximate 133 basis points negative impact from new generic introductions, increased 3.5%. Prescription count at comparable stores increased 1.1% over the prior-year period.
Prescription sales accounted for 69.4% of drug store sales, and third party prescription sales represented 97.4% of pharmacy sales.
FDA advisory committees recommend approval of ultra rapid-acting mealtime insulin therapy
VALENCIA, Calif. — MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.
If approved, AFREZZA would be the first ultra rapid-acting mealtime insulin therapy available in the United States.
"We are pleased with the Advisory Committee’s approval recommendation in support of Afrezza, and we appreciate the thoroughness of their review," stated Alfred Mann, chairman and CEO MannKind Corporation. "We look forward to working with the FDA as they complete their evaluation of Afrezza."
McKesson recognized for McKesson OneCloud technology solution
SAN FRANCISCO — McKesson on Thursday announced that it ranked No. 8 on this year’s InformationWeek Elite 100.
McKesson was recognized for its development of McKesson OneCloud, an internally developed private and public cloud capability used in the development of internal and customer-facing solutions. OneCloud enables McKesson technologists to meet the demands for secure, regulated exchange of healthcare information, while providing the organization with low-cost agile development environments. Taking advantage of economies of scale with OneCloud, the organization can more easily leverage newer technologies to drive business growth, lower costs and reduce development time to more quickly bring solutions to market.
“McKesson is honored to be recognized as one of today’s top technology innovators,” stated Randy Spratt, chief information officer and chief technology officer, McKesson. “As a leader in healthcare, McKesson is committed to evolving our business through the innovative use of technology to shape the future of healthcare and to help our customers and their patients achieve better health.”
OneCloud is a self-service business model serving as the platform for the next generation of McKesson’s products and services. With OneCloud, McKesson business and technology workers can provision new cloud servers or business applications in just minutes. The project speeds up the delivery of business and technology apps used by McKesson’s business units, who in turn serve the company’s external customers, without compromising on security or technology standards.